Although prostate speci®c antigen (PSA) represents a sensitive serum tumour marker for prostate cancer, its use is limited by an insuf®cient speci®city. Therefore, DNA-based molecular tumour markers might increase speci®city in the detection of primary and recurrent prostate cancer. The promoter hypermethylation of the detoxi®cation gene glutathione-S-transferase P1 (GSTP1) is the most consistent DNA alternation in prostatic tumour DNA described so far. 1 This epigenetic DNA alteration has not been found in benign or hyperplastic prostate tissue and it is rare in other malignancies with the exception of liver cancer. GSTP1 promoter hypermethylation should thus constitute an ideal molecular tumour marker for detection of cell-free tumour DNA in the plasma 2 and serum of patients with prostate cancer.
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Method
Thirty-three patients with various stages of prostate cancer and 26 controls with benign prostatic hyperplasia (BPH) were enrolled. DNA was isolated from dissected primary tumours, BPH tissue, nucleated blood cells, plasma and serum. Prior to MSP, DNA was modi®ed by bisulphite treatment resulting in sequence differences depending on methylation status. 3 MSP was carried out using two published,¯uorescently labelled primer pairs targeting a GSTP1 promoter sequence with one primer pair for the methylated reaction (indicating tumour DNA) and the other one for the unmethylated reaction (indicating normal DNA). 4 Fluorescent MSP products were analysed on an automated gene sequencer.
Results
Whereas GSTP1 promoter hypermethylation was not detectable in prostate tissue, the nucleated blood cell fraction, plasma and serum from patients with BPH (speci®city: 100%), we found it in 90% of tumours (18 of 20), 72% of plasma or serum samples (23 of 32) and 30% of nucleated blood cell samples (10 of 33), the latter indicating the presence of circulating prostate tumour cells. In patients with locally advanced or metastatic diseases (T4 and/or M1; n 13), free tumour DNA was detectable in 100% of plasma or serum samples. Notably, GSTP1 promoter hypermethylation was additionally detectable in a limited number of sperm and exprimated urine samples from patients with prostate cancer.
Conclusion
Analysis of GSTP1 promoter hypermethylation by MSP thus provides a speci®c tool for the detection of prostate cancer in the blood. Further experiments on the molecular detection of prostate cancer in bodily¯uids, lymph nodes, surgical margins and bone marrow aspirates are planned to evaluate the usefulness of this DNA-based tumour marker for a molecular staging of prostate cancer. 5 
